Abstracts tagged "citrullinated vimentin"

Abstract Number: 1057 • 2018 ACR/ARHP Annual Meeting
Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts
Eri Sugawara, Masaru Kato, Yuki Kudo, WenShi Lee, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinsuke Yasuda and Tatsuya Atsumi, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Citrullinated vimentin (cVIM) is one of the major autoantigens in patients with rheumatoid arthritis (RA), recognized by anti-citrullinated peptide antibodies. Autophagy is a self-cannibalism…
Abstract Number: 2337 • 2018 ACR/ARHP Annual Meeting
Vertebral Compression Fractures and Antibodies to Citrullinated Vimentin in Established Rheumatoid Arthritis
Jonathan Cheah^1,2, John A. Carrino^3,4, William H. Robinson^5,6, Dana Orange^7,8, Jackie Szymonifka⁹, Emily M. Stein^1,2 and Susan M. Goodman^9,10, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Medicine, Weill Cornell Medicine, New York, NY, ³Radiology, Hospital for Special Surgery, New York, NY, ⁴Radiology, Weill Cornell Medicine, New York, NY, ⁵VA Palo Alto Health Care System, Palo Alto, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Rockefeller University, New York, NY, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Rheumatology, Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with RA have high rates of osteoporosis and fractures and RA induces articular and extra-articular bone loss. Seropositivity for any CCP antibody is…
Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Heidi Kokkonen¹, Mikael Brink², Monika Hansson³, Linda Mathsson⁴, Ewa Lassen⁵, Per Johan Jakobsson⁶, Rikard Holmdahl⁷, Johan Rönnelid⁴, Lars Klareskog⁸ and Solbritt M. Rantapaa-Dahlqvist⁹, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Transfusional Medicin, Umeå University, Umeå, Sweden, ⁶Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis
Lisbeth Arlestig¹, Mikael Brink², Monika Hansson³, Per Johan Jakobsson⁴, Rikard Holmdahl⁵, Linda Mathsson⁶, Johan Ronnelid⁶, Lars Klareskog⁷ and Solbritt M. Rantapaa-Dahlqvist⁸, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁶Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁸Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].